Biologically-Relevant Staphylococcus Aureus Biofilm Phenotype Characterisation And Liability To Novel Antibiofilm Drugs
Objectives: To characterise the biofilm matrix composition of a newly described Staphylococcus aureus biofilm phenotype.
Method: This experimental study was conducted at the Faculty of Pharmacy, Helwan University, Cairo, Egypt, from January 2021 to March 2022, and comprised methicillin-resistant Staphylococcus aureus and methicillin-susceptible Staphylococcus aureus biofilm-forming clinical isolates which were allowed to construct biofilms under two distinct culture conditions; one a commonly used condition, and the other one a novel, more biologically-relevant condition. The formed biofilms were analysed for matrix composition through treatment with proteinase,sodium meta-periodate, and streptokinase. The efficacy of Cis-2-Decenoic acid and hamamelitannin on the biologically-relevant biofilms was evaluated using biofilm viability assay based on a colorimetric assay for measuring cell metabolic activity and scanning electron microscope imaging. Data was analysed using GraphPad Prism 5.01.
RESULTS: Of the 58 isolates, 45(77.6%) were methicillin-resistant Staphylococcus aureus and 13(22.4%) were methicillin susceptible Staphylococcus aureus. There was significant difference in responses to streptokinase, proteinase and sodium meta-periodate (p<0.05) among the differentially-developed biofilms in methicillin-resistant Staphylococcus aureus isolates. Regarding the methicillin-susceptible Staphylococcus aureus isolates, the differentially-developed biofilms showed significantly different liabilities to streptokinase only (p<0.05). Mean biofilm inhibition for Cis-2- Decenoic acid was 54.27±27.93% and mean biofilm dispersion was 71.92±11.59% while the corresponding valuesfor hamamelitannin were 83.03±13.95% and 70.48±7.116% against the newly described methicillin-resistant Staphylococcus aureus biofilm phenotype.
CONCLUSIONS: Applying biologically-relevant culture conditions on staphylococci biofilms and antibiofilm drugs is recommended.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:73(Suppl 4) |
|---|---|
| Enthalten in: |
JPMA. The Journal of the Pakistan Medical Association - 73(Suppl 4)(2023), 4 vom: 24. Apr., Seite S167-S173 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wahman, Shaimaa [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 25.07.2023 Date Revised 25.07.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.47391/JPMA.EGY-S4-34 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359830935 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359830935 | ||
| 003 | DE-627 | ||
| 005 | 20231226081721.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.47391/JPMA.EGY-S4-34 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1199.xml |
| 035 | |a (DE-627)NLM359830935 | ||
| 035 | |a (NLM)37482852 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wahman, Shaimaa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Biologically-Relevant Staphylococcus Aureus Biofilm Phenotype Characterisation And Liability To Novel Antibiofilm Drugs |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.07.2023 | ||
| 500 | |a Date Revised 25.07.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Objectives: To characterise the biofilm matrix composition of a newly described Staphylococcus aureus biofilm phenotype | ||
| 520 | |a Method: This experimental study was conducted at the Faculty of Pharmacy, Helwan University, Cairo, Egypt, from January 2021 to March 2022, and comprised methicillin-resistant Staphylococcus aureus and methicillin-susceptible Staphylococcus aureus biofilm-forming clinical isolates which were allowed to construct biofilms under two distinct culture conditions; one a commonly used condition, and the other one a novel, more biologically-relevant condition. The formed biofilms were analysed for matrix composition through treatment with proteinase,sodium meta-periodate, and streptokinase. The efficacy of Cis-2-Decenoic acid and hamamelitannin on the biologically-relevant biofilms was evaluated using biofilm viability assay based on a colorimetric assay for measuring cell metabolic activity and scanning electron microscope imaging. Data was analysed using GraphPad Prism 5.01 | ||
| 520 | |a RESULTS: Of the 58 isolates, 45(77.6%) were methicillin-resistant Staphylococcus aureus and 13(22.4%) were methicillin susceptible Staphylococcus aureus. There was significant difference in responses to streptokinase, proteinase and sodium meta-periodate (p<0.05) among the differentially-developed biofilms in methicillin-resistant Staphylococcus aureus isolates. Regarding the methicillin-susceptible Staphylococcus aureus isolates, the differentially-developed biofilms showed significantly different liabilities to streptokinase only (p<0.05). Mean biofilm inhibition for Cis-2- Decenoic acid was 54.27±27.93% and mean biofilm dispersion was 71.92±11.59% while the corresponding valuesfor hamamelitannin were 83.03±13.95% and 70.48±7.116% against the newly described methicillin-resistant Staphylococcus aureus biofilm phenotype | ||
| 520 | |a CONCLUSIONS: Applying biologically-relevant culture conditions on staphylococci biofilms and antibiofilm drugs is recommended | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Staphylococcus aureus, Fibrinolytic, Hamamelitannin, Polysaccharide, Polymeric, Fibrin | |
| 650 | 7 | |a hamamelitannin |2 NLM | |
| 650 | 7 | |a Z4320A2K26 |2 NLM | |
| 650 | 7 | |a metaperiodate |2 NLM | |
| 650 | 7 | |a B45A1BUM4Q |2 NLM | |
| 650 | 7 | |a Methicillin |2 NLM | |
| 650 | 7 | |a Q91FH1328A |2 NLM | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Peptide Hydrolases |2 NLM | |
| 650 | 7 | |a EC 3.4.- |2 NLM | |
| 650 | 7 | |a Streptokinase |2 NLM | |
| 650 | 7 | |a EC 3.4.- |2 NLM | |
| 650 | 7 | |a Sodium |2 NLM | |
| 650 | 7 | |a 9NEZ333N27 |2 NLM | |
| 700 | 1 | |a Shawky, Riham Mahmoud |e verfasserin |4 aut | |
| 700 | 1 | |a Emara, Mohamed |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JPMA. The Journal of the Pakistan Medical Association |d 1977 |g 73(Suppl 4)(2023), 4 vom: 24. Apr., Seite S167-S173 |w (DE-627)NLM000033170 |x 0030-9982 |7 nnns |
| 773 | 1 | 8 | |g volume:73(Suppl 4) |g year:2023 |g number:4 |g day:24 |g month:04 |g pages:S167-S173 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.47391/JPMA.EGY-S4-34 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 73(Suppl 4) |j 2023 |e 4 |b 24 |c 04 |h S167-S173 | ||